Paper Details

  1. Home
  2. Paper Details

Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.

Author: AdoriniLuciano, CellaiIlaria, ComeglioPaolo, CorcettoFrancesca, CornoChiara, FilippiSandra, MaggiMario, ManeschiElena, MorelliAnnamaria, PiniAlessandro, SarchielliErica, VannelliGabriella Barbara, VignozziLinda

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Obeticholic acid (OCA), an activator of the farnesoid X receptor (FXR), has shown promise in inhibiting inflammation and fibrosis in liver, kidney, and intestines. FXR activation also suppresses inflammation and promotes lung repair after lung injury. This study investigated the protective effects of OCA treatment on inflammation, tissue remodeling, and fibrosis in a bleomycin-induced pulmonary fibrosis rat model. OCA treatment significantly suppressed pro-inflammatory cytokines, TGF-β1, and SNAI1 expression, suggesting protection against bleomycin-induced lung damage. OCA also improved pulmonary function by normalizing airway resistance and lung stiffness. These results suggest that OCA may offer protection against bleomycin-induced lung fibrosis by targeting key mediators in the pathogenesis of idiopathic pulmonary fibrosis (IPF).
Paper Details　
Original Abstract of the Article :
Farnesoid X receptor (FXR) activation by obeticholic acid (OCA) has been demonstrated to inhibit inflammation and fibrosis development in liver, kidney and intestine in multiple disease models. FXR activation has also been demonstrated to suppress the inflammatory response and to promote lung repair...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jsbmb.2017.01.010

データ提供：米国国立医学図書館（NLM）

Obeticholic Acid: A Potential Oasis for Pulmonary Fibrosis

The fight against [pulmonary fibrosis] is a grueling battle, akin to navigating a treacherous desert landscape. This research explores the potential of [obeticholic acid (OCA)] as a new therapeutic agent for [pulmonary fibrosis]. The authors investigated the effects of OCA in a rat model of bleomycin-induced pulmonary fibrosis, assessing its impact on inflammation, tissue remodeling, and fibrosis development.

OCA Demonstrates Anti-Fibrotic Effects in Pulmonary Fibrosis Model

The researchers found that OCA effectively protected against [bleomycin-induced lung damage], suppressing key molecular mechanisms involved in [epithelial-to-mesenchymal transition (EMT)], [inflammation], and [collagen deposition]. These findings suggest that OCA may offer a potential therapeutic benefit for [pulmonary fibrosis] by targeting multiple pathways involved in the disease process.

A New Horizon for Pulmonary Fibrosis Treatment

This research offers a glimmer of hope for individuals battling [pulmonary fibrosis], suggesting that OCA may hold therapeutic potential. The findings highlight the importance of continued research into new therapies for this debilitating condition. It is crucial to consult with a healthcare professional to discuss the potential benefits and risks of OCA treatment, as well as to determine the best course of action for your individual needs.

Dr.Camel's Conclusion

This research is like a cool breeze in the desert, offering a refreshing perspective on the potential treatment of pulmonary fibrosis. The findings suggest that OCA may offer a promising new approach to managing this complex condition, potentially transforming the lives of those affected. It is a reminder that even in the most challenging of terrains, hope and innovation can flourish.

Date :
  1. Date Completed 2017-07-04
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

28115235

DOI: Digital Object Identifier

10.1016/j.jsbmb.2017.01.010

Related Literature

Article Analysis
・Effects of obeticholic acid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.